Geron Corporation's Rytelo gains FDA approval for MDS treatment, with promising sales and positive analyst outlook. Click ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic ...

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...

Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up to $375 million in synthetic royalty and debt ...

At this time, all participants are in a listen-only mode. Later, there will be a question-and-answer session, and instructions will be given at that time. Please note that today's call is being ...

Good morning, and welcome to the Axsome Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, there will be a question and ...

Detailed price information for Medexus Pharmaceuticals Inc (MDP-T) from The Globe and Mail including charting and trades.

2024 Click here MDS Degree Part 1 (Supplementary) Examinations July 2024 (2018 & 2021 Schemes) September 02, 2024 Click here Third Year BDS Degree Supplementary Examinations, July 2024 (2010 ...

With a talented team and more than 17 years of experience delivering cutting-edge technology, and a very strong balance sheet, we are well positioned ... Syros Announces Topline Data from SELECT-MDS-1 ...

are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) undergoing allogeneic ...